作者: C.J. Griessenauer , C.J. Griessenauer , B. Agee , P.M. Foreman , M.C. Cress
DOI: 10.3174/AJNR.A7002
关键词:
摘要: BACKGROUND: The Pipeline Embolization Device (PED) is a flow-diverting stent for the treatment of intracranial aneurysms and used off-label subset ruptured not amenable to traditional treatment. PURPOSE: Our aim was evaluate safety efficacy PED aneurysms. DATA SOURCES: A systematic review MEDLINE, EMBASE, Scopus data bases from January 2011 March 2020 performed articles reporting with PED. STUDY SELECTION: total 12 studies comprising 145 patients treated were included analysis. ANALYSIS: Individual patient collected. Nonparametric tests compare differences among patients. Logistic regression determine an association outcome variables. SYNTHESIS: Mean aneurysm size 5.9 mm, most blister (51.0%) or dissecting (26.9%) in morphology. Three (2.1%) reruptured following placement. Univariate logistic identified larger as significant predictor rerupture (P = .008). Of radiographic follow-up, 87.5% had complete occlusion. Symptomatic neurologic complications occurred 16.5%. LIMITATIONS: Analysis limited by quality data, which small case series representing class III medical evidence. No study assessed blinded independently adjudicated manner. CONCLUSIONS: Most Treatment associated rate 2.1% occlusion 87.5%.